Identification of synthetic vaccine candidates against SARS CoV infection

Journal Article · Fri Jul 06 00:00:00 EDT 2007 · Biochemical and Biophysical Research Communications

DOI:https://doi.org/10.1016/j.bbrc.2007.04.164· OSTI ID:20991424

Lien, Shu-Pei ^[1]; Shih, Yi-Ping ^[2]; Chen, Hsin-Wei ^[1]; Tsai, Jy-Ping ^[1]; Leng, Chih-Hsiang ^[1]; Lin, Min-Han ^[1]; Lin, Li-Hsiu ^[1]; Liu, Hsin-Yu ^[1]; Chou, Ai-Hsiang ^[1]; Chang, Yu-Wen ^[1]; Chen, Yi-Ming A ^[2]; Chong, Pele ^[1]; Liu, Shih-Jen ^[1]

---

1. Vaccine Research and Development Center, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan (China)
2. AIDS Prevention and Research Center, National Yang-Ming University, Taipei, Taiwan (China)

Three peptides, D1 (amino acid residues 175-201), D2 (a.a. 434-467), and TM (a.a. 1128-1159), corresponding to the spike protein (S) of severe acute respiratory syndrome corona virus (SARS CoV) were synthesized and their immunological functions were investigated in three different animals models (mice, guinea pigs, and rabbits). The peptides mixture formulated either with Freund's adjuvant or synthetic adjuvant Montanide ISA-51/oligodeoxy nucleotide CpG (ISA/CpG) could elicit antisera in immunized animals which were capable of inhibiting SARS/HIV pseudovirus entry into HepG2 cells. The neutralizing epitopes were identified using peptides to block the neutralizing effect of guinea pig antisera. The major neutralizing epitope was located on the D2 peptide, and the amino acid residue was fine mapped to 434-453. In BALB/c mice T-cell proliferation assay revealed that only D2 peptide contained T-cell epitope, the sequence of which corresponded to amino acid residue 434-448. The ISA/CpG formulation generated anti-D2 IgG titer comparable to those obtained from Freund's adjuvant formulation, but generated fewer antibodies against D1 or TM peptides. The highly immunogenic D2 peptide contains both neutralizing and Th cell epitopes. These results suggest that synthetic peptide D2 would be useful as a component of SARS vaccine candidates.

• OSTI ID: 20991424
• Journal Information: Biochemical and Biophysical Research Communications, Vol. 358, Issue 3; Other Information: DOI: 10.1016/j.bbrc.2007.04.164; PII: S0006-291X(07)00882-0; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
AIDS VIRUS
AMINO ACIDS
ANTIBODIES
CELL PROLIFERATION
GUINEA PIGS
MICE
NUCLEOTIDES
PEPTIDES
RABBITS
VACCINES